---
title: "U.S. stock market quick update: Bristol-Myers Squibb receives FDA approval and analysts raise expectations, stock price surges 26.10%!"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278573883.md"
description: "Bristol-Myers Squibb Company rose by 26.10%"
datetime: "2026-03-10T14:51:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278573883.md)
  - [en](https://longbridge.com/en/news/278573883.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278573883.md)
generator: "portal-rs"
---

# U.S. stock market quick update: Bristol-Myers Squibb receives FDA approval and analysts raise expectations, stock price surges 26.10%!

**U.S. Stock Market Midday Update**

Bristol-Myers Squibb rose 26.10%. Based on recent key news:

1.  On March 8, Bristol-Myers Squibb received FDA approval for its drug to treat adult psoriatic arthritis. This approval expands the drug's applicability and enhances market expectations for the company's future growth, driving the stock price up by 26.10%. Source: Zhitong Finance

2.  On March 7, analysts raised their earnings expectations for Bristol-Myers Squibb, anticipating a significant increase in market demand for its new drugs. This optimistic earnings forecast boosted investor confidence, further driving the stock price up. Source: Wall Street Insight

3.  On March 6, Bristol-Myers Squibb announced a collaboration agreement with a biotechnology company aimed at jointly developing new treatment solutions. This collaboration is expected to accelerate the R&D process for innovative drugs and enhance the company's long-term competitiveness, positively impacting the stock price. Source: Jinshi Data, recent policy support for the pharmaceutical industry, significant capital inflow

### Related Stocks

- [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md)

## Related News & Research

- [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md)
- [Illinois Tool Works Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/296616962.md)
- [ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | TAK Stock News](https://longbridge.com/en/news/296745786.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)
- [Erasca's Pancreatic Cancer Drug Gains FDA Fast Track Designation](https://longbridge.com/en/news/296791914.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**